Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target

Current Medicinal Chemistry
Giulia ManinaGiovanna Riccardi

Abstract

Tuberculosis is still a leading cause of death in developing countries and a resurgent disease in developed countries. The selection and soaring spread of Mycobacterium tuberculosis multidrug-resistant (MDR-TB) and extensively drug-resistant strains (XDR-TB) is a severe public health problem. Currently, there is an urgent need of new drugs for tuberculosis treatment, with novel mechanisms of action and, moreover, the necessity to identify new drug targets. Several enzymes involved in various metabolic processes have been described as potential targets for the development of new drugs. Recently, two different classes of most promising drugs, the benzothiazinones (BTZ) and the dinitrobenzamide derivatives (DNB), have been found to be highly active against M. tuberculosis, including XDR-TB strains. Interestingly, both drugs have the same target: the heteromeric decaprenylphosphoryl-β-D-ribose 2'-epimerase encoded by dprE1 (Rv3790) and dprE2 (Rv3791) genes, respectively. DprE1 and DprE2 are involved in the biosynthesis of D-arabinose and, in particular, they are essential to perform the transformation of decaprenylphosphoryl-D-ribose to decaprenylphosphoryl-D-arabinose, which is a substrate for arabinosyltransferases in the synthes...Continue Reading

Citations

Jun 27, 2012·Proceedings of the National Academy of Sciences of the United States of America·Sarah M BattGurdyal S Besra
Nov 3, 2012·The Journal of Antimicrobial Chemotherapy·Chun-Taek OhJichan Jang
Sep 8, 2012·Science Translational Medicine·João NeresClaudia Binda
Nov 10, 2011·PloS One·Ana Luisa de Jesus Lopes RibeiroMaria Rosalia Pasca
Apr 1, 2014·European Journal of Medicinal Chemistry·Sana AslamJamshed Iqbal
Apr 25, 2012·Applied Microbiology and Biotechnology·Silvia BuroniGiovanna Riccardi
Oct 28, 2015·Future Medicinal Chemistry·Deepak KumarDiwan S Rawat
Dec 12, 2013·Expert Opinion on Therapeutic Targets·Geetha Vani Rayasam
May 6, 2016·Interdisciplinary Sciences, Computational Life Sciences·Richa Anand
Aug 9, 2011·Current Opinion in Microbiology·Stewart T Cole, Giovanna Riccardi
Aug 28, 2016·FEMS Microbiology Reviews·Christina Schäffer, Paul Messner
Nov 9, 2016·Journal of Drug Targeting·Nzungize LambertJianping Xie
Jun 30, 2019·Medicinal Research Reviews·Aparna Bahuguna, Diwan S Rawat
Mar 6, 2019·Current Topics in Medicinal Chemistry·Marcus Vinicius Nora de Souza, Thais Cristina Mendonça Nogueira
Jun 17, 2011·The Journal of Biological Chemistry·Hanjeong HarveyLori L Burrows
Apr 2, 2020·Antimicrobial Agents and Chemotherapy·Norimitsu HariguchiMakoto Matsumoto
Jun 25, 2018·Chemistry Central Journal·Jineetkumar Gawad, Chandrakant Bonde
Jan 20, 2021·Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents·Gang ZhangCourtney C Aldrich
May 14, 2014·Journal of Medicinal Chemistry·Manoranjan PandaAnandkumar Raichurkar
Jul 16, 2014·The Journal of Organic Chemistry·Shivaji A ThadkeSrinivas Hotha

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Bacterial Cell Wall Structure

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Bacterial Cell Wall Structure (ASM)

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.